It is estimated that approximately 3–5% of all colorectal cancers may manifest the Lynch syndrome while its familial adenomatous polyposis counterpart accounts for less than 1% of the total colorectal cancer burden. Familial aggregation constitutes approximately 20% of all colorectal cancer occurrences. What does this mean to the geneticist, diagnostician, and ultimately the high-risk patient? Clearly, family history is the key, and when germline pathogenic mutations are identified within a family, one is then in the enviable position of providing a significant reduction in patients’ cancer morbidity and mortality through highly-targeted screening and management. Confounders for each high-risk family will be the syndrome’s phenotypic and genotypic heterogeneity, and therein it will be best comprehended through study of its natural history. In some cases the syndrome’s complexity may be beyond the physician’s knowledge, and help will then be available through referral to genetic counselors or centers of cancer genetics expertise. Finally, basic science and clinical studies on high-risk families harbor enormous opportunities to uncover etiology and pathogenesis which may ultimately translate into cancer prevention in both hereditary and sporadic forms of cancer.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.